Peptide Schedule
TRT (Testosterone Replacement Therapy)Small moleculeNo amino acid sequence. Icon reflects category theme only.TRT (Testosterone Replacement Therapy)
Benefits
About TRT (Testosterone Replacement Therapy)
Testosterone Replacement Therapy (TRT) is the medical use of exogenous testosterone to restore serum levels in men diagnosed with hypogonadism — defined as total testosterone consistently below 300 ng/dL on two separate morning blood draws. The FDA approved testosterone cypionate (Depo-Testosterone) for this indication decades ago, and it remains the most widely prescribed injectable form in the United States. Testosterone enanthate is equally effective with a nearly identical pharmacokinetic profile. TRT is prescribed when the body can't produce enough testosterone on its own, whether from primary testicular failure, pituitary dysfunction, aging-related decline, or prior use of anabolic steroids that suppressed the HPTA. Symptoms of low testosterone include fatigue, reduced libido, erectile dysfunction, loss of muscle mass, increased body fat, depressed mood, and poor concentration. Injectable testosterone cypionate comes in 10 mL multi-dose vials at 200 mg/mL concentration. It's an oil-based solution (typically in cottonseed or grapeseed oil) injected intramuscularly or subcutaneously. Unlike peptides, there's no reconstitution required — you draw directly from the vial. The 2023 TRAVERSE trial (n=5,246) established cardiovascular safety in men with pre-existing CV risk, finding testosterone was noninferior to placebo for major adverse cardiac events (HR 0.96, 95% CI 0.78-1.17). This was a landmark result that resolved years of debate about cardiac safety. TRT requires ongoing monitoring. Hematocrit must be checked regularly — if it exceeds 54%, dose reduction or therapeutic phlebotomy is needed. PSA should be tracked for prostate safety. Estradiol management matters because testosterone aromatizes to estrogen, which can cause water retention, gynecomastia, and mood changes if levels climb too high.
Who Should Consider TRT (Testosterone Replacement Therapy)
- Men with diagnosed hypogonadism (total testosterone consistently below 300 ng/dL)
- Men with age-related testosterone decline and symptomatic low T
- Post-anabolic steroid users with suppressed HPTA seeking medically supervised restoration
- Men with secondary hypogonadism from pituitary dysfunction or chronic opioid use
- Transgender men undergoing masculinizing hormone therapy
How TRT (Testosterone Replacement Therapy) Works
Testosterone cypionate is an esterified prodrug. After intramuscular injection into the gluteal or deltoid muscle, the oil depot slowly releases testosterone cypionate into surrounding tissue. Esterases in the blood cleave the cypionate ester, liberating free testosterone. This free testosterone binds to androgen receptors (AR) in the cytoplasm of target cells throughout the body — skeletal muscle, bone, brain, adipose tissue, skin, and reproductive organs. The testosterone-AR complex translocates to the nucleus where it acts as a transcription factor, binding androgen response elements (AREs) on DNA to upregulate protein synthesis, particularly in muscle tissue (myosin heavy chain, IGF-1 local production). In bone, AR activation stimulates osteoblast proliferation and inhibits osteoclast activity, increasing mineral density. Testosterone also undergoes two key enzymatic conversions: 5-alpha reductase converts it to dihydrotestosterone (DHT), a more potent androgen responsible for prostate growth and hair follicle effects; and aromatase converts it to estradiol (E2), which is necessary for bone health and libido but problematic in excess. In the hypothalamus, rising testosterone and estradiol exert negative feedback on GnRH pulsatility, which suppresses LH and FSH from the pituitary — this is why exogenous testosterone causes testicular atrophy and impaired spermatogenesis.
What to Expect
Testosterone levels begin rising within 24-48 hours of the first injection. Most men don't notice subjective changes yet. Slight improvements in energy and mood may appear toward week 2-3. Serum trough levels aren't stable until about 4-5 half-lives (~5-6 weeks).
Libido and sexual function often improve noticeably. Morning erections return in previously hypogonadal men. Energy and motivation begin to pick up. First follow-up labs should be drawn at 6 weeks (trough level, before next injection).
Body composition changes start — early increases in lean mass and reductions in visceral fat. Mood stabilizes. Hematocrit may begin climbing. Estradiol should be checked. Dose adjustments are commonly made at this stage based on bloodwork.
Full effects on muscle mass, strength, and fat loss become apparent. Bone mineral density improvements are measurable. Red blood cell count and hematocrit reach new equilibrium — monitor closely. Lipid panel changes may appear (HDL may decrease slightly).
Maximum therapeutic benefits are reached by 9-12 months. Body composition, mood, libido, and energy reach steady state. Ongoing monitoring every 6-12 months: CBC, metabolic panel, testosterone, estradiol, PSA, and lipids.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 80mg | Weekly |
| Moderate | 75mg | 2x/week |
| Aggressive | 100mg | 2x/week |
Note: TRT isn't a peptide — it's exogenous testosterone, but it's commonly stacked with peptides like gonadorelin or HCG for fertility preservation. Testosterone cypionate and enanthate are the two most common injectable esters. Always get baseline bloodwork before starting: total testosterone, free testosterone, estradiol, SHBG, CBC with hematocrit, PSA, and a lipid panel. Recheck labs at 6 weeks, 3 months, 6 months, then every 6-12 months. Splitting your weekly dose into 2 injections (every 3.5 days) produces more stable blood levels and reduces estrogen spikes. Aromatase inhibitors like anastrozole should only be used if estradiol climbs above 40-50 pg/mL with symptoms — don't crash your estrogen.
How to Inject TRT (Testosterone Replacement Therapy)
Testosterone cypionate is injected intramuscularly using a 23-25 gauge, 1-1.5 inch needle. Common injection sites are the ventrogluteal (preferred for safety and absorption), vastus lateralis (outer thigh), and deltoid. Draw the oil using an 18-20 gauge drawing needle, then switch to the injection needle. Warm the vial in your hands for 60 seconds — warm oil flows more easily. Inject slowly over 15-20 seconds to reduce post-injection pain. Aspirate briefly before injecting to confirm you're not in a blood vessel. Rotate injection sites each time to prevent scar tissue buildup. Some clinicians now support shallow IM or subcutaneous injection with a 27-29 gauge, 0.5 inch insulin syringe into abdominal or thigh fat — studies show comparable absorption with less pain.
Cycling Protocol
TRT is a continuous, lifelong therapy — not cycled. Stopping abruptly causes a crash in testosterone levels that can take months to recover from (if natural production recovers at all). If discontinuation is desired, work with an endocrinologist on a PCT protocol using enclomiphene, gonadorelin, or HCG to restart the HPG axis.
Pharmacokinetics
Source: FDA label — terminal half-life ~8 days (192 hours) for testosterone cypionate IM; Bi et al. 2018 population PK study reported median post-hoc half-life of 4.05 days for total testosterone appearance
Loading the interactive decay curve.
Side Effects
Hematocrit elevation is the most common lab abnormality — testosterone stimulates erythropoiesis, and levels above 54% increase blood viscosity and clot risk. Therapeutic phlebotomy or dose reduction may be needed. Testosterone aromatizes to estradiol via the aromatase enzyme, which can cause gynecomastia, water retention, and mood swings if estrogen climbs too high. Acne and oily skin affect roughly 15-25% of users, particularly on the shoulders and back. DHT-mediated hair loss accelerates in men genetically predisposed to male pattern baldness. TRT suppresses the HPG axis, shrinking the testes and drastically reducing sperm production — men wanting future fertility should use HCG or gonadorelin concurrently. The TRAVERSE trial found higher rates of pulmonary embolism and atrial fibrillation versus placebo, though these were secondary endpoints. PSA may increase modestly; men with untreated prostate cancer should not use TRT. Sleep apnea can worsen in susceptible individuals. Mood irritability and increased aggression are occasionally reported, typically at supraphysiologic doses.
Contraindications
- Prostate cancer (current or history of hormone-sensitive prostate cancer)
- Male breast cancer
- Polycythemia (hematocrit above 54%) — withhold until resolved
- Severe untreated sleep apnea
- Uncontrolled heart failure (NYHA Class III-IV)
- Desire for near-term fertility without concurrent gonadotropin support
- Pregnancy or potential exposure to pregnant women (teratogenic — Category X)
- Known hypersensitivity to testosterone or any formulation component
- Unevaluated prostate nodule or PSA above 4 ng/mL without urological clearance
Drug Interactions
- Anticoagulants (warfarin, heparin) — testosterone may increase INR and bleeding risk; monitor closely and adjust dose
- Insulin and oral hypoglycemics — testosterone can improve insulin sensitivity, potentially causing hypoglycemia; dose adjustment may be needed
- Corticosteroids — concurrent use increases edema risk due to sodium and fluid retention
- Aromatase inhibitors (anastrozole, exemestane) — commonly co-prescribed but over-suppression of estradiol causes joint pain, low libido, and bone loss
- CYP3A4 inhibitors (ketoconazole, ritonavir) — may increase testosterone levels by slowing hepatic metabolism
- 5-alpha reductase inhibitors (finasteride, dutasteride) — block conversion to DHT, may reduce androgenic side effects but also limit some benefits
Storage & Stability
Related Peptides
References
- Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE Trial) — Lincoff et al., NEJM 2023PubMed 37326322
- Efficacy and Adverse Events of Testosterone Replacement Therapy in Hypogonadal Men — Corona et al., J Clin Endocrinol Metab 2018PubMed 29562364
- Depo-Testosterone (testosterone cypionate) — FDA Prescribing Information, Pfizer 2018FDA Label